12:00 AM
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avastin bevacizumab: Phase III data

Researchers at the National Surgical Adjuvant Breast and Bowel Project and colleagues reported data from the North American Phase III NSABP-B-40 trial in 1,206 patients with operable HER2-negative breast cancer showing that the addition of Avastin to neoadjuvant chemotherapy (docetaxel plus doxorubicin and cyclophosphamide alone or in combination with capecitabine or gemcitabine) significantly increased the proportion of patients achieving a pCR, the primary endpoint, vs. chemotherapy alone (34.5% vs. 28.2%,...

Read the full 329 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >